PubMed Health⌕ Search

Biomedical subjects

Y Han

Publications and source records attributed to Y Han.

At least 235 records · Page 13Linked to original sources
PubMed1997

[Identification of realgar and arsenopyrite and their sublimates].

In this paper, two traditional Chinese medicinal minerals realgar and arsenopyrite, as well as their sublimates are identified in their nature, physical and optical properties, chemical compositions and trace elements. The result has shown that there are marked differences among realgar, arsenopyrite and their sublimates, and it should be particularly noted that the difference between the two sublimates will certainly affect the quality of the two minerals that are used as poisonous drug in China.

Arsenic Trioxide↗
PubMed1997

[Human tolerance to landing impact (+Gz) in sitting position].

The study showed that macaca mulatta selected can be used as a substitute for human in studying tolerance to landing impact. Based on the data of the experiments, the revisional coefficient from macaca mulatta to humans was calculated, and curves of human tolerance to landing impact in sitting position were given. Tolerance limits for different injuries such as safe, slight injury, medium injury and serious injury are also given in this paper. The results might be useful for setting human tolerance standards to landing impact in sitting position.

Acceleration↗
PubMed1997

[Simultaneous determination of five carotenoids in tomato by reversed-phase high performance liquid chromatography].

A reversed-phase high performance liquid chromatographic method for the simultaneous determination of alpha-carotene, beta-carotene, gamma-carotene, lycopene and canthaxanthin in tomato has been developed. These carotenoids were extracted with acetone and petroleum ether (1:1) directly. The extract was dried by N2 stream. The residue was dissolved in methanol and separated on a micro-Bondapak C18 (Waters) column 150 mm x 3.9 mm i.d., acetonitrile:dichloromethane:methanol (85:10:5) as mobile phase. It was then detected at 450 nm by UV/VIS spectrophotometer. The retention times of alpha-carotene, beta-carotene, gamma-carotene, lycopene and canthaxanthin by simultaneous determination were 15.25, 16.12, 12.87, 10.38 and 5.37 min, respectively. Detection limits were 0.25, 0.22, 0.18, 0.14 and 0.05 mg/L. Recoveries were 92.38%, 94.33%, 92.40%, 93.21% and 96.40%, respectively. The coefficients of variation were 2.6%, 3.5%, 2.8%, 2.8% and 3.3%, respectively. The method was simple, rapid and accurate.

Carotenoids↗
PubMed1997

Preferential inhibition of glioblastoma cells with wild-type epidermal growth factor receptors by a novel tyrosine kinase inhibitor ethyl-2,5-dihydroxycinnamate.

Epidermal growth factor receptor (EGFR) gene overexpression and mutations play an important role in the pathogenesis of a variety of malignant human cancers. In this study, we tested the effects of a novel EGFR tyrosine kinase inhibitor, ethyl-2,5-dihydroxycinnamate (EtDHC), against related human glioblastoma cell lines expressing specific forms of EGFR gene mutations. EtDHC more potently inhibited cell growth and DNA synthesis in glioblastoma cells with endogenous or overexpressed wild-type EGFR compared with those with truncated EGFR, by preferentially inhibiting the tyrosine kinase activity and autophosphorylation of the wild-type EGFR. Higher concentrations of EtDHC were required to inhibit cells expressing the truncated EGFR. These findings are the reverse of another highly specific tyrosine kinase inhibitor, tyrphostin AG 1478, which preferentially inhibited glioblastoma cells with truncated EGFR compared with those with wild-type EGFR. The differential susceptibility of various glioblastoma cells to highly specific tyrosine kinase inhibitors is significant because human gliomas are composed of heterogeneous cells with subsets of cells expressing specific gene mutations. This cellular heterogeneity could be one of the reasons why tumor cells are resistant to chemotherapy. Thus, EtDHC, especially when in combination with drugs targeting other specific gene mutations (such as tyrphostin AG 1478), holds a significant potential for chemotherapy for human glioblastomas.

Cell Division↗
PubMed1997

Identification of a novel missense mutation in Wilson's disease gene.

OBJECTIVE: To investigate the allelic heterogeneity of the ATP7B gene in Chinese patients with Wilson's disease (WD). METHODS: Exons of the ATP7B gene from 141 WD patients' DNA were amplified with polymerase chain reaction (PCR) 887-890. Mutations were then screened by single strand conformation polymorphism (SSCP) analysis and further identified by sequencing. RESULTS: The molecular structure of exon 7 of the ATP7B gene from 141 WD patients was analyzed. The same band shift in electrophoretic pattern of 4 cerebral type patients was identified with SSCP and subsequently sequenced. The results showed missense mutation at the second base of the codon as Ser 662 Cys, which is caused by a C to G transversion. CONCLUSIONS: Mutations of the ATP7B gene were investigated for the first time in China and a novel missense mutation was identified in four cases.

Adolescent↗
PubMed1996

hCG beta residues 94-96 alter LH activity without appearing to make key receptor contacts.

The ability of human chorionic gonadotropin (hCG) to distinguish lutropin (LHR) and follitropin (FSHR) receptors is controlled principally by beta-subunit residues 94-117. To learn how residues 94-96 (Arg-Arg-Ser) influence LHR binding, we studied the effects of replacing them on the LH and FSH activities of a bifunctional hCG analog in which residues 101-109 were derived from FSH. Analogs containing 1-3 arginines and no aspartates at residues 94-96 bound LHR with 25-400% the potency of hCG. When residues 94-96 were neutral or contained 1-3 aspartates, LHR binding was reduced 6-100 fold but remained at least ten-fold greater than the negative control analog containing residues 94-117 derived from FSH. Residues 94-96 had little influence on FSHR binding. These observations support a model [Moyle et al. (1995) J. Biol. Chem. 270:20,020] in which residues 94-96 influence LHR binding specificity primarily through an effect on hormone conformation rather than by direct participation in essential high affinity receptor contacts.

Amino Acid Sequence↗
PubMed1996

Interaction of a fluorescent derivative of paclitaxel (Taxol) with microtubules and tubulin-colchicine.

A fluorescent derivative of paclitaxel, 2-debenzoyl-2-(m-aminobenzoyl)paclitaxel (2-AB-PT), has been prepared. 2-AB-PT induces microtubule assembly in vitro, but is about 3-fold less potent than paclitaxel itself. The absorption and emission characteristics of 2-AB-PT were analyzed as a function of solvent. It was found that both spectra were perturbed by specific solvent effects when the solvent contained a hydrogen bond donor. The absorption and fluorescence spectra of 2-AB-PT bound to microtubules could not be mimicked by a single solvent, but the absorption and emission maxima of the tubulin-bound species could be duplicated by a solvent mixture of DMSO and water. These results indicate that the fluorophore binding site on the microtubule is in an environment of intermediate polarity that is accessible to a hydrogen bond donor in the vicinity of the m-amino group. In addition, tubulin fluorescence is quenched in the 2-AB-PT/microtubule complex, and energy transfer from tubulin to 2-AB-PT is apparent. These results indicate that substituents on the C-2 position of paclitaxel associate with tubulin when bound to the microtubule. 2-AB-PT binding to microtubules was quantitatively analyzed by fluorescence titrations. Two classes of binding sites for 2-AB-PT on microtubules were found. The high affinity site has an apparent association constant (K1app) of 2.0 (+/- 0.9) x 10(7) M-1 and an apparent binding stoichiometry (n1app) of 0.8 (+/- 0.1) sites/tubulin dimer in the microtubule. The apparent association constant for the lower affinity site is about 100-fold less than that of the higher affinity site (K2app = 2.1 (+/- 0.7) x 10(5) M-1), and the stoichiometry of the lower affinity site or class of sites (n2app) was found to be 1.3 +/- 0.1. Paclitaxel blocked 2-AB-PT binding to the high affinity site. No binding of 2-AB-PT to unassembled tubulin was observed, but the emission spectrum of 2-AB-PT in the presence of the tubulin-colchicine complex resembled the emission spectrum of the ligand bound to microtubules. It was previously shown that paclitaxel can induce GTPase activity in the tubulin-colchicine complex, indicating that paclitaxel can bind to unassembled tubulin in its complex with colchicine [Carlier, M.-F., & Pantaloni, D. (1983) Biochemistry 22, 4814-4822]. Rigorous characterization of the aggregation state of the protein under these conditions demonstrates that 2-AB-PT is also capable of binding to the tubulin-colchicine complex.

Animals↗
PubMed1996

Tyrphostin AG 1478 preferentially inhibits human glioma cells expressing truncated rather than wild-type epidermal growth factor receptors.

The effects of a new epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, tyrphostin AG 1478, were tested on three related human glioma cell lines: U87MG, which expressed endogenous wild-type (wt) EGFR, and two retrovirally infected U87MG cell populations which over-expressed either wt (U87MG.wtEGFR) or truncated EGFR (U87MG. delta EGFR). Although AG 1478 inhibited cell growth, DNA synthesis, EGFR tyrosine kinase activity, and receptor autophosphorylation of each cell line in a dose-dependent manner, it was significantly more potent in U87MG. delta EGFR cells than in the other two cell lines. The increased inhibitory response of U87MG. delta EGFR cells was due to a greater sensitivity of the constitutively autophosphorylated Mr 140,000 and 155,000 delta EGFR species to AG 1478. These results suggest that AG 1478 is a relatively specific inhibitor of the delta EGFR, and this finding may have important therapeutic implications since the delta EGFR occurs frequently in glioblastomas and in breast, lung, and ovarian cancers.

Benzylidene Compounds↗
PubMed1996

Hospitalization of patients infected with active TB in New York State, 1987-1992: the effect of the HIV epidemic.

Hospital discharge records were used to study the relationship between human immunodeficiency virus (HIV) epidemic and hospitalized patients with tuberculosis in New York State from 1987 through 1992. The discharges of patients coinfected with HIV and tuberculosis increased by 270%, rising from 1,573 in 1987 to 5,825 in 1992. This constitutes an increase from 19.8 to 49.1% of all discharges of patients with tuberculosis. Discharges of tuberculosis patients who were not infected with HIV decreased slightly during this time, going from 6,359 to 6,039. Postdischarge treatment plans, HIV prevention, HIV testing, and HIV educational programs for the tuberculosis population require special consideration, given the significant rise of HIV in the tuberculosis-infected population.

AIDS-Related Opportunistic Infections↗
PubMed1996

Medial amygdaloid suppression of predatory attack behavior in the cat: I Role of a substance P pathway from the medial amygdala to the medial hypothalamus.

The medial amygdala is known to powerfully suppress predatory attack behavior in the cat, but the mechanisms underlying such modulation remain unknown. The present study tested the hypothesis that medial amygdaloid suppression of predatory attack is mediated, in part, by a pathway from the medial amygdala to the medial hypothalamus which utilizes substance P as a neurotransmitter. Stimulating electrodes were implanted into the medial amygdala and cannula electrodes were implanted into both the medial and lateral hypothalamus. Predatory attack behavior was elicited by electrical stimulation of the lateral hypothalamus. In the first phase of the study, paired trials compared attack latencies of single stimulation of the lateral hypothalamus with those following dual stimulation of the lateral hypothalamus and medial amygdala. Attack latencies were significantly elevated following dual stimulation of the medial amygdala and lateral hypothalamus. In the second phase of the study, dose and time dependent decreases in response suppression were noted following the infusion of the substance P (NK1) receptor antagonist, CP96.345 (in doses of 0.05, 0.5 and 2.5 nmol) into the medial hypothalamus. In third phase of the study, the effects of microinjections of the substance P receptor agonist, [Sar9.Met(O2)11]-substance P (in doses of 0.5, 1.0 and 2.0 nmol), directly into the medial hypothalamus upon lateral hypothalamically elicited predatory attack behavior were determined. Microinfusion of this drug elevated attack response latencies in a dose- and time-dependent manner. In addition, pretreatment with CP96,345 into the medial hypothalamus blocked the suppressive effects of subsequent delivery of [Sar9,Met(O2)11]-substance P into the same medial hypothalamic site. Other parts of the study demonstrated the presence of: (1) high densities of substance P receptors in the ventromedial hypothalamus, and (2) neurons that are positively labeled for substance P that project from the medial amygdala to the ventromedial hypothalamus as demonstrated by retrograde labeling with Fluoro-Gold. These findings provide support for the hypothesis that medial amygdaloid suppression of lateral hypothalamically elicited predatory attack behavior includes a substance P pathway from the medial amygdala to the medial hypothalamus. The findings further suggest that stimulation of the medial amygdala activates substance P receptors in the medial hypothalamus, thus triggering an inhibitory mechanism from the medial to the lateral hypothalamus, resulting in suppression of predatory attack behavior.

Amygdala↗
PubMed1996

Medial amygdaloid suppression of predatory attack behavior in the cat: II. Role of a GABAergic pathway from the medial to the lateral hypothalamus.

The medial amygdala is known to powerfully suppress predatory attack behavior elicited by electrical stimulation of the lateral hypothalamus of the cat. In the preceding paper, it was shown that the initial limb of a pathway subserving suppression of predatory attack from the medial amygdala to the lateral hypothalamus projects to the ventromedial hypothalamus and its functions are mediated by substance P. The present study tested the hypothesis that the second limb of the pathway subserving medial amygdaloid suppression of predatory attack behavior projects from the medial to lateral hypothalamus and its functions are mediated by GABA. Cannula electrodes were implanted into the lateral hypothalamus for elicitation of predatory attack behavior as well as for the microinfusion of GABA compounds. Monopolar stimulating electrodes were implanted into sites within the medial amygdala from which subseizure levels of stimulation could suppress predatory attack behavior. Initially, the effects of dual stimulation of the medial amygdala and lateral hypothalamus upon response latencies for predatory attack were compared with single stimulation of the lateral hypothalamus alone. Dual stimulation was shown to significantly suppress predatory attack elicited from the lateral hypothalamus. Then, the GABAA receptor antagonist, bicuculline, was microinjected into sites within the lateral hypothalamus from which predatory attack was elicited in doses of 0.015, 0.075 and 0.15 nmol and paired trials of single and dual stimulation were again repeated in a manner identical to that applied prior to drug administration. Drug infusion produced a blockade of medial amygdaloid suppression of predatory attack in a time- and dose-dependent manner. Conversely, microinfusions of the GABAA receptor agonist, muscimol (10, 25 and 50 pmol), into the same lateral hypothalamic 'attack' site in the absence of medial amygdaloid stimulation suppressed predatory attack, thus simulating the effects of medial amygdaloid stimulation. Furthermore, pretreatment with bicuculline microinjected into the lateral hypothalamus blocked the suppressive effects of substance P, that was infused into the ventromedial hypothalamus, upon predatory attack. Receptor autoradiography demonstrated the presence of high affinity binding for GABAA receptors in the lateral hypothalamus. A combination of immunocytochemical and retrograde axonal tract tracing procedures, in which Fluoro-Gold was microinjected into the lateral hypothalamic attack sites, revealed the presence of populations of neurons labeled for both Fluoro-Gold and GABA in the ventromedial hypothalamus. These findings provide new evidence for the existence of a pathway from the medial to lateral hypothalamus whose functions are mediated by GABA. Thus, the overall findings provide support for the view that the pathway from the medial amygdala to the lateral hypothalamus underlying suppression of predatory attack behavior involves a two-neuronal arc: the first neuron projects from the medial amygdala to the medial hypothalamus and its functions are mediated by substance P: the second neuron involves a GABAergic pathway originating in the ventromedial hypothalamus and which projects to the lateral hypothalamus.

Amygdala↗
PubMed1996

Participation of JAK and STAT proteins in growth hormone-induced signaling.

The binding of growth hormone leads to dimerization of its receptor, accompanied by phosphorylation and activation of intracellular tyrosine kinases (JAKs) and the latent cytoplasmic transcriptions factors STAT1, STAT3, and STAT5. Both JAK1 and JAK2 are phosphorylated in response to growth hormone in mouse 3T3 F442A and human HT1080 cells. The roles of JAKs in growth hormone signal transduction were examined by using mutant HT1080 cells missing either JAK1 or JAK2. JAK2 is absolutely required for growth hormone-dependent phosphorylation of the receptor, STAT1 and STAT3, JAK1, and the SH2-containing adaptor molecule Shc. In contrast, JAK1 is not required for any of the above functions. These data indicate that JAK2 is both necessary and sufficient for the growth hormone-dependent phosphorylation events required to couple the receptor both to STAT-dependent signaling pathways and to pathways involving Shc. Furthermore, STAT5 is activated by growth hormone in 3T3 F442A cells, but not in HT1080 cells, revealing that the set of STATs activated by growth hormone can vary, possibly contributing to the specificity of the growth hormone response in different cell types.

3T3 Cells↗
PubMed1996

Expression of 32-kDa laminin-binding protein mRNA in colon cancer tissues.

Colorectal cancer initiation and progression are associated with stepwise genetic alterations. We and others have shown that a gene encoding for a 32-kDa putative laminin-binding protein (LBP-32) is overexpressed during colorectal cancer progression by Northern blots analysis. Northern blots cannot indicate the heterogeneity of expression from cell to cell and the distribution pattern of gene expression within a given tumor. In order to overcome these problems, we examined the LBP-32 mRNA expression in colorectal carcinomas by in situ hybridization. LBP-32 mRNA expression in 30 cases of primary and metastatic colorectal cancers and their respective adjacent normal tissues were detected by in situ hybridization using 35S-UTP radiolabeled antisense riboprobes. The results showed that LBP-32 mRNA was expressed at a low level in the normal colonic mucosa adjacent to the tumor compared with colon cancer tissues. Its expression in poorly differentiated colorectal cancer was much higher than that in well- and moderately differentiated colorectal cancer. More importantly, the LBP-32 mRNA was expressed more highly in the invasive lesions of the cancer and liver metastases compared with the cancer lesions in situ. Our results imply that in situ hybridization is a powerful tool in evaluating the changes in gene expression in the cancer cells and LBP-32 mRNA expression is related to progression, invasion, and metastasis of colorectal cancer.

Carcinoma↗